Abstract
Germline variants explain a minority of Lung Cancer (LC) cases. Accumulating evidence have shown a role of genes of the Fanconi pathway, such as BRCA2, CHEK2 and PALB2, in LC. Suggested features of LC patients (pts) carrying germline mutations are young pts, pts with double primary tumor, and cancer family history (CFH). Nowadays, guidelines for genetic testing (GT) in LC have not been published. GT could provide benefits such as target therapy and cascade testing for relatives. Herein, we describe the result of germline GT with a Multigene (MPG) panel in LC pts.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call